Preliminary evidence came from both clinical development of PHD enzyme inhibitors and experimental research suggests that augmenting HIF signaling to stimulate EPO production is an attractive strategy for the treatment of anemia of CKD (Souma et al., 2016; Locatelli et al., 2017). The gene discussed is PDC; the disease is anemia (phenotype).